ORLANDO, Fla.—Relative survival rates for patients with advanced renal cell carcinoma (RCC) have not improved significantly in the era of targeted agents, according to data presented at the annual Genitourinary Cancers Symposium.
Binay K. Shah, MD, of Saint Joseph Regional Medical Center in Lewiston, Idaho, and Krishna B. Ghimire, MD, of Mercy Medical Center North Iowa in Mason City, Iowa, analyzed data from the Surveillance, Epidemiology, and End Results (SEER)-18 registry database to compare one- and three-year relative survival rates among patients with advanced RCC during 2001-2009, 2001-2004, and 2006-2009. The total number of advanced RCC patients during 2001-2009, 2001-2004, and 2006-2009 were 7,055, 3,355, and 2,985, respectively.
During 2001-2009, the one- and three-year relative survival rates were 26.7% and 10%, respectively. The one-year relative survival rates during 2001-2004 and 2006-2009 were 27% and 27%, respectively. The three-year survival rates were 10% and 9.6%, respectively.